Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands
Tóm tắt
Inhibition of dipeptidyl peptidase (DPP-)4 could reduce coronavirus disease 2019 (COVID-19) severity by reducing inflammation and enhancing tissue repair beyond glucose lowering. We aimed to assess this in a prospective cohort study. We studied in 565 patients with type 2 diabetes in the CovidPredict Clinical Course Cohort whether use of a DPP-4 inhibitor prior to hospital admission due to COVID-19 was associated with improved clinical outcomes. Using crude analyses and propensity score matching (on age, sex and BMI), 28 patients using a DPP-4 inhibitor were identified and compared to non-users. No differences were found in the primary outcome mortality (matched-analysis = odds-ratio: 0,94 [95% confidence interval: 0,69 – 1,28], p-value: 0,689) or any of the secondary outcomes (ICU admission, invasive ventilation, thrombotic events or infectious complications). Additional analyses comparing users of DPP-4 inhibitors with subgroups of non-users (subgroup 1: users of metformin and sulphonylurea; subgroup 2: users of any insulin combination), allowing to correct for diabetes severity, did not yield different results. We conclude that outpatient use of a DPP-4 inhibitor does not affect the clinical outcomes of patients with type 2 diabetes who are hospitalized because of COVID-19 infection.
Tài liệu tham khảo
Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813–21.
Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782–92.
Sathish T, Cao Y. What is the role of admission HbA1c in managing COVID-19 patients? J Diabetes. 2021;13(3):273–5.
Sathish T, Mello GT, Cao Y. Is newly diagnosed diabetes a stronger risk factor than pre-existing diabetes for COVID -19 severity? J Diabetes. 2021;13(2):177–8.
Eleftheriou P, Amanatidou D, Petrou A, Geronikaki A. In silico evaluation of the effectivity of approved protease Inhibitors against the main protease of the novel SARS-CoV-2 virus. Molecules. 2020;25(11):2529.
Shinjo T, Nakatsu Y, Iwashita M, et al. DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation. Am J Physiol Endocrinol Metab. 2015;309(3):E214–23.
Kawasaki T, Chen W, Htwe YM, Tatsumi K, Dudek SM. DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. Am J Physiol Cell Mol Physiol. 2018;315(5):L834–45.
Tang Y, liu J, zhang d, et al. cytokine storm in covid-19: the current evidence and treatment Strategies. Front Immunol. 2020;11:1708.
Zhong J, Rajagopalan S. Dipeptidyl peptidase-4 regulation of SDF-1/CXCR4 axis: implications for cardiovascular disease. Front Immunol. 2015;6:477.
Solerte SB, D’Addio F, Trevisan R, et al. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and covid-19: a multicenter case-control retrospective observational study. Diabetes Care. 2020;43(12):2999–3006.
Prokop M, Van Everdingen W, Van Rees VT, et al. CO-RADS: A Categorical CT Assessment Scheme for Patients Suspected of Having COVID-19-Definition and Evaluation. Radiology. 2020;296(2):E97-104.
teffects psmatch - propensity score matching. Stata Manuals v13.
Rakhmat II, Kusmala YY, Handayani DR, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr Clin Res Rev. 2021;15(3):777–82.
Hariyanto TI, Kurniawan A. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression. J Diabetes Metab Disord. 2021.
Dalan R, Ang LW, Tan WYT, et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. Eur Hear J Cardiovasc Pharmacother. 2021;7(3):e48-51.